License

Asep Medical Holdings Inc. Signs Joint Venture Agreement with Leading Chinese Medical Diagnostics Company Sansure Biotech Inc.

Retrieved on: 
Wednesday, November 22, 2023
Medicine, FSE, CSE, Transaction, End-user license agreement, Meta-analysis, Mortality, Septic shock, BioMed Central, Sepsis, PCR, Strategic planning, Side letter, Warrant, Death, RMB, License, Emergency medicine, ASEP, JV, Patent, Security (finance), Asep

VANCOUVER, BC, Nov. 21, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce that, through its subsidiary Sepset Biosciences Inc. ("Sepset"), it has signed a definitive joint venture agreement (the "JV Agreement") with leading Chinese medical diagnostic company, Sansure Biotech Inc. ("Sansure"), through its subsidiary, Hunan Xiang Jiang Sansure Biotech Fund, L.P. (the "Sansure Fund").

Key Points: 
  • VANCOUVER, BC, Nov. 21, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce that, through its subsidiary Sepset Biosciences Inc. ("Sepset"), it has signed a definitive joint venture agreement (the "JV Agreement") with leading Chinese medical diagnostic company, Sansure Biotech Inc. ("Sansure"), through its subsidiary, Hunan Xiang Jiang Sansure Biotech Fund, L.P. (the "Sansure Fund").
  • Sansure Fund is an investment fund formed by Sansure, Changsha Sanway Spring Venture Capital CO., Ltd. ("Sanway Spring") and certain other investors.
  • Formal registration of SepSMART with the applicable regulatory body in China is a condition precedent of the JV Agreement.
  • We look forward to collaborating with the Sansure team as we bring this technology to market in China."

BROADPEAK SA: Publication by Broadpeak of its third-quarter 2023 revenue

Retrieved on: 
Thursday, December 7, 2023
Policy, Workforce, License, IPO, Software as a service, Growth, Earnings before interest, taxes, depreciation and amortization, Maintenance

At 30 September 2023, the Group’s revenue totalled €25.95 million (€m), versus €25.7 million during the first nine months of reporting year 2022, an 0.9% increase.

Key Points: 
  • At 30 September 2023, the Group’s revenue totalled €25.95 million (€m), versus €25.7 million during the first nine months of reporting year 2022, an 0.9% increase.
  • The macroeconomic context also weighed on the pace of commercial transformation of orders currently being negotiated.
  • By 2026, the Group expects a doubling of the share of recurring revenue to 40% of revenue (compared with 20% in 2021).
  • As a reminder, Broadpeak is targeting sales of €100 million by this date, with an Ebitda margin of 20% (compared with 9% in 2021).

Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.

Retrieved on: 
Thursday, November 9, 2023
Research, Infectious Diseases, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Wellcome Trust, Government, FDA, Biomedical Advanced Research and Development Authority, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Meropenem, PDUFA, Food, Cutis laxa, United States Department of Health and Human Services, Pyelonephritis, Melinta Therapeutics, End-user license agreement, Prescription Drug User Fee Act, Human services, Regulation of tobacco by the U.S. Food and Drug Administration, Urinary tract infection, R, Administration, QIDP, CDC, Pseudomonas aeruginosa, Regulation, Medicine, Partnership, Infection, AP, ESBL, NDA, License, Therapy, Patient, Bangladesh Technical Education Board, Pharmaceutical industry

The partnership follows Venatorx’s submission of a New Drug Application (NDA) for cefepime-taniborbactam for the treatment of cUTI including pyelonephritis, in adults.

Key Points: 
  • The partnership follows Venatorx’s submission of a New Drug Application (NDA) for cefepime-taniborbactam for the treatment of cUTI including pyelonephritis, in adults.
  • Venatorx has been assigned a Prescription Drug User Fee Act (PDUFA) target action date for February 22, 2024.
  • The U.S. Food and Drug Administration (FDA) granted cefepime-taniborbactam Qualified Infectious Disease Product (QIDP) and Fast Track designations for both the cUTI and HABP/VABP indications.
  • Venatorx has granted GARDP exclusive rights to distribute and sub-distribute cefepime-taniborbactam, once it is approved for clinical use, in low- and lower middle-income countries.

Ontarians Rally Behind Hospitals' Split the Pot Lottery

Retrieved on: 
Wednesday, November 8, 2023
Patient, License, BC Children's Hospital Foundation, Hospital, Better Online Tickets Sales Act, Auction, Nursing

TORONTO, Nov. 8, 2023 /CNW/ - Ontarians have unequivocally demonstrated their unwavering commitment to supporting healthcare through a groundbreaking initiative—the Hospitals' Split the Pot Lottery.

Key Points: 
  • TORONTO, Nov. 8, 2023 /CNW/ - Ontarians have unequivocally demonstrated their unwavering commitment to supporting healthcare through a groundbreaking initiative—the Hospitals' Split the Pot Lottery.
  • Ascend Fundraising Solutions (Ascend), through its regulated subsidiaries and affiliates, is providing cutting-edge software and lottery consulting services for the Split the Pot Lottery.
  • The Split the Pot Lottery offers players a fresh opportunity to win significant prizes while contributing to the largest partnered fundraising initiative in Ontario.
  • This marks only the beginning of the journey with Split the Pot Lottery.

NANOBIOTIX Announces Closing of Global Offering

Retrieved on: 
Tuesday, November 7, 2023
Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, Bloomberg, License, State Street, Guggenheim, Guggenheim Partners, Jefferies Group, Telephone, Form, Additional notification thresholds, Cancer, Patient, Security (finance), The 8th Floor, Floor, NANO, ADS, Madison Avenue, Private, Option, Attention, Prospectus, EU, Euronext

The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.

Key Points: 
  • The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
  • Jefferies LLC, Leerink Partners and Guggenheim Securities acted as global coordinators and joint bookrunners for the Global Offering.
  • The ADSs (including the Additional ADSs) and Ordinary Shares offered in the Global Offering were offered pursuant to an effective shelf registration statement on Form F-3 (Registration No.
  • The Global Offering was made only by means of a prospectus and prospectus supplement that form a part of the registration statement.

NANOBIOTIX Announces Closing of Global Offering

Retrieved on: 
Tuesday, November 7, 2023
Common stock, Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, Bloomberg, License, State Street, Guggenheim, Guggenheim Partners, Jefferies Group, Telephone, Form, Additive manufacturing file format, Cancer, Patient, Security (finance), The 8th Floor, Floor, NANO, ADS, Madison Avenue, Note, AMF, Private, Option, Attention, Prospectus, EU, Euronext

PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the closing today (the “Closing”) of its global follow-on offering reserved to specified categories of investors, including after partial exercise by the underwriters of their option to purchase additional ordinary shares (the “Underwriters’ Option”) in the form of American Depositary Shares (“ADSs”).

Key Points: 
  • PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the closing today (the “Closing”) of its global follow-on offering reserved to specified categories of investors, including after partial exercise by the underwriters of their option to purchase additional ordinary shares (the “Underwriters’ Option”) in the form of American Depositary Shares (“ADSs”).
  • The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
  • Jefferies LLC, Leerink Partners and Guggenheim Securities acted as global coordinators and joint bookrunners for the Global Offering.
  • The Global Offering was made only by means of a prospectus and prospectus supplement that form a part of the registration statement.

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

Retrieved on: 
Tuesday, November 7, 2023
FDA, Janssen, Organon, G&A, Inflammation, Place of birth, NDA, License, End-user license agreement, Glioma, Video game, Cryptocurrency, Pharmaceutical industry

EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its third quarter 2023 financial results and highlighted recent portfolio activities expected to drive long-term shareholder value.

Key Points: 
  • XOMA recorded total revenues of $0.8 million for the third quarter of 2023 and $0.5 million for the third quarter of 2022.
  • General and administrative (“G&A”) expenses were $6.4 million for the third quarter of 2023, compared to $4.8 million for the third quarter of 2022.
  • In the third quarter of 2023, G&A expenses included $2.7 million in non-cash stock-based compensation expense, compared with $0.8 million in the third quarter of 2022.
  • Other income, net was $0.3 million for the third quarter of 2023 and $0.2 million in the corresponding quarter of 2022.

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Research, Seizure, Therapy, ASO, Behavior, American Epilepsy Society, Dravet syndrome, Syndrome, OLE, Medicine, Collaboration, Acadia Pharmaceuticals, Brain, Safety, License, AES, Patient, Cognition, Pharmaceutical industry, Cryptocurrency, Stoke

These data, along with encouraging feedback from clinicians, support our belief that STK-001 is a disease-modifying approach that is moving treatment beyond seizure management to address the syndrome.

Key Points: 
  • These data, along with encouraging feedback from clinicians, support our belief that STK-001 is a disease-modifying approach that is moving treatment beyond seizure management to address the syndrome.
  • Following an analysis of these data, the Company plans to meet with regulators to discuss a Phase 3 study design.
  • As of September 30, 2023, Stoke had $214.7 million in cash, cash equivalents, and marketable securities, which is anticipated to fund operations to the end of 2025.
  • General and administrative expenses for the nine months ended September 30, 2023, were $30.7 million, compared to $29.5 million for the same period in 2022.

PurMinds Triples its Psilocybin-Containing Mushroom Propagation Yields and Increases its Inventory of Dried Psilocybe Cubensis Strains for Supply to Clinical Trials and Authorized Medical Clinics World-Wide

Retrieved on: 
Tuesday, November 7, 2023
WHO, FDA, MDMA, Radioisotope Production Facility, Psilocybin, Mycology, Prohibition of drugs, EMA, Psilocybe, Safety, License, General counsel, Pharmaceutical industry

The Company is current growing weekly with authorization to store up to 250,000 kg of dried psilocybin-containing mushrooms on-site, or the equivalent of 1,250 kg of psilocybin.

Key Points: 
  • The Company is current growing weekly with authorization to store up to 250,000 kg of dried psilocybin-containing mushrooms on-site, or the equivalent of 1,250 kg of psilocybin.
  • PurMinds™ is currently able to supply its psilocybin mushrooms in dried whole mushroom form, or milled and encapsulated, with potency analyses reaching average total tryptamine levels of up to 1.03%.
  • To support patient safety and practitioner confidence, each batch is also tested for impurities.
  • "The specialized expertise that our scientists and cultivation team possess, coupled with the Company's strong focus on safety, efficacy and profitability, has ideally positioned PurMinds to be at the forefront of legal natural psilocybin mushroom supply."

Globalstar Announces Third Quarter 2023 Results

Retrieved on: 
Thursday, November 2, 2023
Technology, Mobile, Wireless, Finance, Banking, Accounting, Telecommunications, Professional Services, Software, Networks, GSAT, XCOM, ARPU, NYSE, SPOT, Duplex, Public expenditure, MG, EBITDA, License, GAAP, Maintenance, Gen4 Energy, Growth, Commercial, Ecosystem, Webcast, Total, End-user license agreement, Loral, Video game, Television, Mobile phone, Financial adviser, Bank, Bookkeeping, Music, Cryptocurrency, Globalstar

Globalstar, Inc. (NYSE American: GSAT) today announced its operating and financial results for the third quarter and year to date period ended September 30, 2023.

Key Points: 
  • Globalstar, Inc. (NYSE American: GSAT) today announced its operating and financial results for the third quarter and year to date period ended September 30, 2023.
  • Total revenue increased $20.1 million, or 53%, to $57.7 million during the third quarter of 2023 compared to the third quarter of 2022, due to higher service revenue.
  • Second quarter 2023 was the first full quarter of normal production of these devices, and we have seen a correlated increase in activations.
  • Subscriber equipment sales decreased $0.3 million or 7% in the third quarter of 2023 compared to the third quarter of 2022.